KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
[Safety profile of tenofovir amibufenamide therapy extension or switching in patients with chronic hepatitis B: a phase Ⅲ multicenter, randomized controlled trial].Zhonghua Gan Zang Bing Za ZhiPMID 39528324PMC128989392024-Oct-200.98未发现恶性肿瘤人群证据。待处理
Combined immunogenicity evaluation for a new single-dose live-attenuated chikungunya vaccine.J Travel MedPMID 38959854无 PMCID2024-Oct-190.98未发现恶性肿瘤人群证据。待处理
Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39419054无 PMCID2024-Oct-190.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47.RMD OpenPMID 39424404PMC114929372024-Oct-180.98未发现恶性肿瘤人群证据。待处理
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.N Engl J MedPMID 39413375PMC114886442024-Oct-170.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.N Engl J MedPMID 39413377PMC76167142024-Oct-170.95Eligible Phase III randomized trial with primary time-to-event endpoint, but excluded because intervention is radiotherapy, not a drug-containing intervention.待处理
A double-blind, placebo-controlled, randomised withdrawal study of adjunctive brexpiprazole maintenance treatment for major depressive disorder.Acta NeuropsychiatrPMID 39415650PMC131303222024-Oct-170.98未发现恶性肿瘤人群证据。待处理
Postoperative C5 Palsy after Anterior or Posterior Decompression for Degenerative Cervical Myelopathy: A Subgroup Analysis of the Multicenter, Prospective, Randomized, Phase III, CSM-Protect Clinical Trial.Spine (Phila Pa 1976)PMID 38616732无 PMCID2024-Oct-150.98未发现恶性肿瘤人群证据。待处理
Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical Programme.J Crohns ColitisPMID 38700040PMC114797122024-Oct-150.98未发现恶性肿瘤人群证据。待处理
Efficacy of golimumab in rheumatoid arthritis patients at high risk of a poor prognosis: Post hoc analysis of GO-FORTH study using cluster analysis.Mod RheumatolPMID 38780239无 PMCID2024-Oct-150.98未发现恶性肿瘤人群证据。待处理
Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: Analysis of the phase 3 VISION trial.CancerPMID 39031642PMC118512342024-Oct-150.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial.Clin Infect DisPMID 39099085PMC114785882024-Oct-150.98未发现恶性肿瘤人群证据。待处理
Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of Age.Clin Infect DisPMID 39099093PMC114785782024-Oct-150.98未发现恶性肿瘤人群证据。待处理
A Phase III Randomized Controlled Trial of Plitidepsin, a Marine-Derived Compound, in Hospitalized Adults With Moderate COVID-19.Clin Infect DisPMID 39182994PMC114785862024-Oct-150.98未发现恶性肿瘤人群证据。待处理
Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial.Cardiovasc ResPMID 38753448PMC114811692024-Oct-140.98未发现恶性肿瘤人群证据。待处理
Efficacy, immunogenicity, and safety of a monovalent mRNA vaccine, ABO1020, in adults: A randomized, double-blind, placebo-controlled, phase 3 trial.MedPMID 39025066无 PMCID2024-Oct-110.98未发现恶性肿瘤人群证据。待处理
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.J Clin OncolPMID 38819031PMC114581012024-Oct-100.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39268857无 PMCID2024-Oct-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.Blood AdvPMID 39024542PMC114650392024-Oct-080.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD+ acute myeloid leukemia.Blood AdvPMID 39167766PMC114604462024-Oct-080.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 study.BMJ OpenPMID 39384241PMC114749222024-Oct-080.98未发现恶性肿瘤人群证据。待处理
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.LancetPMID 39284329PMC122082112024-Oct-050.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39288779无 PMCID2024-Oct-050.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Effects of oral sepiapterin on blood Phe concentration in a broad range of patients with phenylketonuria (APHENITY): results of an international, phase 3, randomised, double-blind, placebo-controlled trial.LancetPMID 39368841无 PMCID2024-Oct-050.98未发现恶性肿瘤人群证据。待处理
Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer.OncologistPMID 38815152PMC114491142024-Oct-030.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
A phase 3 non-inferiority trial of locally manufactured Meningococcal ACWY vaccine 'Ingovax ACWY' among Bangladeshi adults.VaccinePMID 38897895无 PMCID2024-Oct-030.98未发现恶性肿瘤人群证据。待处理
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.N Engl J MedPMID 38912654PMC115986642024-Oct-030.98未发现恶性肿瘤人群证据。待处理
Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic.VaccinePMID 38937182无 PMCID2024-Oct-030.98未发现恶性肿瘤人群证据。待处理
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.N Engl J MedPMID 39046157无 PMCID2024-Oct-030.98未发现恶性肿瘤人群证据。待处理
Phase III randomized clinical trial of efficacy and safety of amlodipine and candesartan cilexetil combination for hypertension treatment.Sci RepPMID 39358448PMC114470832024-Oct-030.98未发现恶性肿瘤人群证据。待处理
Effects of Antihypertensive Therapy During Pregnancy on Postpartum Blood Pressure Control.Obstet GynecolPMID 39265175无 PMCID2024-Oct-010.98未发现恶性肿瘤人群证据。待处理
Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study.Rheumatology (Oxford)PMID 38258434PMC114430352024-Oct-010.98未发现恶性肿瘤人群证据。待处理
Late Urinary Toxicity and Quality of Life With Pelvic Radiation Therapy for High-Risk Prostate Cancer: Dose-Effect Relations in the POP-RT Randomized Phase 3 Trial.Int J Radiat Oncol Biol PhysPMID 38552989无 PMCID2024-Oct-010.95The report is an original result from a randomized Phase 3 oncology trial in humans with time-to-event endpoints. However, the intervention is radiation therapy alone without a drug-containing component, which is a required criterion for eligibility in this cohort.待处理
Efficacy and Toxicity of Moderately Hypofractionated Radiation Therapy with Helical TomoTherapy Versus Conventional Radiation Therapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer Receiving Concurrent Chemotherapy: A Multicenter, Randomized Phase 3 Trial.Int J Radiat Oncol Biol Phys疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 38631536无 PMCID2024-Oct-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Long-term outcomes of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection (IOCCRC): a randomized, multicenter, prospective, phase III trial.Int J SurgPMID 38652147PMC114870292024-Oct-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。部分完成
The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival.HaematologicaPMID 38813715PMC114433712024-Oct-010.99记录类型属于综述、Meta 分析、社论、评论、病例或指南。待处理
Effect of local prolonged-release incisional doxycycline on surgical site infection prophylaxis in abdominal colorectal surgery: the SHIELD 1 randomized clinical trial.Int J SurgPMID 38869970PMC114869982024-Oct-010.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.AIDSPMID 38905488PMC113657542024-Oct-010.98未发现恶性肿瘤人群证据。待处理
Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study.J Natl Cancer InstPMID 38913881PMC114611622024-Oct-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Mepolizumab in CRSwNP/ECRS and NP: the phase III randomised MERIT trial in Japan, China, and Russia.RhinologyPMID 39058315无 PMCID2024-Oct-010.98未发现恶性肿瘤人群证据。待处理
Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial.Clin Cancer ResPMID 39058425PMC114432472024-Oct-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of a Presurgical Toolkit (OPTI-Surg)-Final Results of a Phase III Cluster Randomized Trial (Alliance A231601CD).Ann SurgPMID 39069901PMC117287682024-Oct-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.Clin Cancer ResPMID 39087959PMC114432082024-Oct-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Bifidobacterium and Lactobacillus Probiotics and Gut Dysbiosis in Preterm Infants: The PRIMAL Randomized Clinical Trial.JAMA PediatrPMID 39102225PMC125491432024-Oct-010.98未发现恶性肿瘤人群证据。待处理
Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical Trial.JAMA DermatolPMID 39141364PMC113252392024-Oct-010.98未发现恶性肿瘤人群证据。待处理
Tranexamic Acid in Patients Undergoing Liver Resection: The HeLiX Randomized Clinical Trial.JAMAPMID 39158894PMC113340132024-Oct-010.85The trial is a randomized Phase III study in cancer patients, but the intervention is not a cancer-specific drug therapy (it is tranexamic acid for perioperative bleeding reduction), and the primary efficacy endpoint is not a time-to-event outcome (e.g., OS, PFS, DFS).待处理
RELATIONSHIP BETWEEN OPTICAL COHERENCE TOMOGRAPHY BIOMARKERS AND NUMBER OF INTRAVITREAL RANIBIZUMAB INJECTIONS IN EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE HARBOR STUDY.RetinaPMID 39287532无 PMCID2024-Oct-010.98未发现恶性肿瘤人群证据。待处理
EFFICACY AND SAFETY OF THE PROPOSED BIOSIMILAR AFLIBERCEPT, SDZ-AFL, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 52-Week Results From the Phase 3 Mylight Study.RetinaPMID 39287533PMC113982902024-Oct-010.98未发现恶性肿瘤人群证据。待处理
Patiromer Facilitates Angiotensin Inhibitor and Mineralocorticoid Antagonist Therapies in Patients With Heart Failure and Hyperkalemia.J Am Coll CardiolPMID 39322323无 PMCID2024-Oct-010.98未发现恶性肿瘤人群证据。待处理
Baseline characteristics associated with the first year treatment interval of intravitreal faricimab in neovascular age-related macular degeneration (nAMD).BMJ Open OphthalmolPMID 39353678PMC114481282024-Oct-010.98未发现恶性肿瘤人群证据。待处理